The pill that changes the manufacturing math: a small-molecule oral GLP-1 agonist, once daily, no food-and-water ritual — ≈−11–12% at top dose in ATTAIN-1’s 2025 topline. Not yet approved; the first true mass-scale moment awaits its filing.
Deeper data: the trial index holds every figure above with sources; the oral file, the pill-wave trend call.
Orforglipron is not approved and cannot be legitimately purchased. It matters anyway: a once-daily pill that activates the GLP-1 receptor without being a peptide — no injections, no fasting ritual, and manufacturing that scales like ordinary tablets.
Why a small molecule changes the equation
Peptides like semaglutide barely survive the gut — hence injections, or Rybelsus’s ~1%-absorption workaround. A small molecule dodges the problem: orforglipron’s label-defining feature in trials has been dosing with no food or water restrictions. Just as importantly, tablet-scale synthesis could eventually undercut the injector-pen supply economics that keep list prices high.
What the trials have shown
In ACHIEVE-1 (type 2 diabetes, 2025), orforglipron cut A1c substantially with roughly 7–8% weight loss at the top dose. Company-reported topline results from ATTAIN-1 (obesity, 2025) put average weight loss around 12% at 72 weeks — below tirzepatide’s bar, in injectable-semaglutide territory, from a pill. Treat topline numbers as provisional until peer-reviewed publication, and verify the current regulatory status: filings were expected on a fast timeline as of our last verification. Full context in the oral pipeline file.
The consumer warning that writes itself
Every high-profile pipeline molecule spawns gray-market “research” vendors selling powders with its name. No legitimate telehealth program can prescribe orforglipron today; anything sold under the name is untested at best (gray-market file).
What approval would actually change
Two things, in order. Capacity: tablets scale in ways sterile injector pens never will, which attacks the supply ceiling that made the 2022–2024 shortages possible. Price structure: a mass-manufacturable daily pill gives payers and cash channels a lever against injectable pricing across the whole class — including the compounded market this site’s ledger tracks, whose core customer is someone priced out of brand injectables. A credible oral at injectable-semaglutide efficacy re-prices everything around it.
What we’ll verify at launch
If and when approval lands: the real list price versus the pill-scale promise; day-one insurance behavior; whether a self-pay channel launches alongside; and how fast gray-market counterfeits of the name proliferate (they already exist). Until then, the standing rule: nothing sold today as orforglipron is legitimate, anywhere, at any price.
What trial dosing looked like
Studies ran once-daily tablets across multiple dose arms with stepwise escalation — but without Rybelsus-style fasting choreography, which is the whole point of the chemistry. Any product today claiming to be orforglipron in capsules, drops, or “research liquid” is counterfeit by definition; the molecule has never left the trial supply chain.
References
ACHIEVE-1, NEJM 2025; ATTAIN-1 topline, company disclosure 2025 — verify against subsequent publications and FDA actions.